{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:13:14Z","timestamp":1788250394766,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011300","name":"Department of Pediatrics, University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008235","name":"School of Medicine, University of Utah Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jcf.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T16:22:24Z","timestamp":1719418944000},"page":"1010-1019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"given":"Anindit","family":"Chhibber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Hikiji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollyann","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Kharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakil M.","family":"Syeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Sherwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-0984","authenticated-orcid":false,"given":"Joseph","family":"Biskupiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-9054","authenticated-orcid":false,"given":"Venkata K.","family":"Yellepeddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-6359","authenticated-orcid":false,"given":"Diana","family":"Brixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-7257","authenticated-orcid":false,"given":"David C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0001","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.pcl.2016.04.001","article-title":"Background and Epidemiology","volume":"63","author":"Sanders","year":"2016","journal-title":"Pediatr Clin North Am"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.006_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2015.10.002","article-title":"Epidemiology of Cystic Fibrosis","volume":"37","author":"Spoonhower","year":"2016","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Animal Model Exp Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J Transl Med"},{"issue":"19","key":"10.1016\/j.jcf.2024.06.006_bib0006","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0007","first-page":"248","article-title":"Association of medication regimen complexity with clinical endpoints in pediatric patients with cystic fibrosis","volume":"26","author":"Tjugum","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.006_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0009","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.4103\/0976-500X.120957","article-title":"Clinical and economic burden of adverse drug reactions","volume":"4","author":"Sultana","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.006_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm J"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0011","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/ageing\/21.4.294","article-title":"Inappropriate medication is a major cause of adverse drug reactions in elderly patients","volume":"21","author":"Lindley","year":"1992","journal-title":"Age Ageing"},{"issue":"12","key":"10.1016\/j.jcf.2024.06.006_bib0012","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1021\/acs.jmedchem.9b01297","article-title":"Understanding idiosyncratic toxicity: lessons learned from drug-induced liver injury","volume":"63","author":"Mosedale","year":"2020","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.jcf.2024.06.006_bib0013","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2125.1998.00817.x","article-title":"Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies","volume":"46","author":"Martin","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0014","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13293-021-00377-0","article-title":"Sex differences associated with adverse drug reactions resulting in hospital admissions","volume":"12","author":"Hendriksen","year":"2021","journal-title":"Biol Sex Differ"},{"issue":"7","key":"10.1016\/j.jcf.2024.06.006_bib0015","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study","volume":"85","author":"de Vries","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.jcf.2024.06.006_bib0017","first-page":"1061","article-title":"Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs","volume":"11","author":"Moore","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.jcf.2024.06.006_bib0018","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3325\/cmj.2011.52.604","article-title":"Adverse drug reactions caused by drug-drug interactions reported to croatian agency for medicinal products and medical devices: a retrospective observational study","volume":"52","author":"Mirosevic Skvrce","year":"2011","journal-title":"Croat Med J"},{"key":"10.1016\/j.jcf.2024.06.006_bib0019","article-title":"Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database","volume":"11","author":"Magro","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0020","first-page":"114","article-title":"Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review","volume":"72","author":"Bozina","year":"2021","journal-title":"Arh Hig Rada Toksikol"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug-drug-gene interactions and adverse drug reactions","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"9","key":"10.1016\/j.jcf.2024.06.006_bib0022","first-page":"630","article-title":"Drug-gene interactions: inherent variability in drug maintenance dose requirements","volume":"39","author":"Westervelt","year":"2014","journal-title":"P T"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0023","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cpt.2348","article-title":"Drug-Drug-Gene Interactions: a Call for Clinical Consideration","volume":"110","author":"Bruckmueller","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jcf.2024.06.006_bib0024","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/pgs.14.6","article-title":"How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping","volume":"15","author":"Verbeurgt","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcf.2024.06.006_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.651720","article-title":"Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine","volume":"12","author":"Micaglio","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2024.06.006_bib0026","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/17512433.2019.1597706","article-title":"The role of pharmacogenomics in adverse drug reactions","volume":"12","author":"Cacabelos","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0027","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.phrs.2003.05.003","article-title":"Adverse drug reactions: role of pharmacogenomics","volume":"49","author":"Severino","year":"2004","journal-title":"Pharmacol Res"},{"issue":"18","key":"10.1016\/j.jcf.2024.06.006_bib0028","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","article-title":"Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review","volume":"286","author":"Phillips","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ppul.25809","article-title":"Opportunity for pharmacogenomic testing in patients with cystic fibrosis","volume":"57","author":"Sakon","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.jcf.2024.06.006_bib0031","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2217\/pgs-2022-0025","article-title":"Pharmacogenomics: a tool to improve medication safety and efficacy in patients with cystic fibrosis","volume":"23","author":"Sakon","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcf.2024.06.006_bib0032","unstructured":"ARUP Laboratories. Cytochrome P450 Genotyping 2021 [cited 2022]. Available from: https:\/\/ltd.aruplab.com\/api\/ltd\/pdf\/186."},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0033","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/dmd.115.067900","article-title":"Interindividual variability in cytochrome P450-mediated drug metabolism","volume":"44","author":"Tracy","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.006_bib0034","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12024-010-9188-3","article-title":"Review: pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects","volume":"7","author":"Pilgrim","year":"2011","journal-title":"Forensic Sci Med Pathol"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0035","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jcf.2024.06.006_bib0036","unstructured":"Consortium; CPI. What is CPIC? 2022. Available from: https:\/\/cpicpgx.org\/."},{"key":"10.1016\/j.jcf.2024.06.006_bib0037","unstructured":"DPWG. Dutch Pharmacogenetics Working Group 2022. Available from: https:\/\/www.pharmgkb.org\/page\/dpwg."},{"issue":"10374","key":"10.1016\/j.jcf.2024.06.006_bib0038","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.006_bib0039","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00008571-199412000-00001","article-title":"Biochemistry and molecular biology of the human CYP2C subfamily","volume":"4","author":"Goldstein","year":"1994","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2125.2004.02183.x","article-title":"The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects","volume":"59","author":"Martinez","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0041","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jcf.2024.06.006_bib0042","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","article-title":"CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes","volume":"64","author":"Bahadur","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0043","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/tpj.2009.10","article-title":"Global variation in CYP2C8-CYP2C9 functional haplotypes","volume":"9","author":"Speed","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jcf.2024.06.006_bib0044","unstructured":"DPWG. PGx Gene-specific Information Tables 2022. Available from: https:\/\/www.pharmgkb.org\/page\/pgxGeneRef."},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.0306-5251.2001.01460.x","article-title":"Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population","volume":"52","author":"Scordo","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jcf.2024.06.006_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/genes11111295","article-title":"A review of the important role of CYP2D6 in pharmacogenomics","volume":"11","author":"Taylor","year":"2020","journal-title":"Genes (Basel)"},{"issue":"8","key":"10.1016\/j.jcf.2024.06.006_bib0047","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2217\/pgs.14.27","article-title":"CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects","volume":"15","author":"Leeder","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0048","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/pgs.14.28","article-title":"CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects","volume":"15","author":"Gaedigk","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0049","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bcp.12227","article-title":"CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials","volume":"77","author":"Penas-Lledo","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.DMPK-11-RV-121","article-title":"Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance","volume":"27","author":"Teh","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.006_bib0051","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.006_bib0052","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00008571-199812000-00010","article-title":"CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles","volume":"8","author":"Leathart","year":"1998","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0053","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovic","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0054","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0055","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m14937","article-title":"CYP2D6 genotyping and inhibition as predictors of adverse drug reactions in depressive disorders","volume":"85","author":"Holck","year":"2024","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.006_bib0056","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.jcf.2024.06.006_bib0057","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FPC.0b013e328351d47f","article-title":"PharmGKB summary: very important pharmacogene information for CYP3A5","volume":"22","author":"Lamba","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"2\u20133","key":"10.1016\/j.jcf.2024.06.006_bib0058","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/DMR-120023681","article-title":"PM frequencies of major CYPs in Asians and Caucasians","volume":"35","author":"Mizutani","year":"2003","journal-title":"Drug Metab Rev"},{"issue":"7","key":"10.1016\/j.jcf.2024.06.006_bib0059","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-018-2450-4","article-title":"Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries","volume":"74","author":"van Dyk","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.jcf.2024.06.006_bib0060","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"van Schaik","year":"2002","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.jcf.2024.06.006_bib0061","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.105.003822","article-title":"CYP3A5 genetic polymorphisms in different ethnic populations","volume":"33","author":"Roy","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.006_bib0062","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jcf.2024.06.006_bib0063","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/bs.apha.2018.04.002","article-title":"Pharmacogenetics in Cardiovascular Medicine","volume":"83","author":"Weeke","year":"2018","journal-title":"Adv Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0064","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40142-016-0096-z","article-title":"Pharmacogenetics in Cardiovascular Medicine","volume":"4","author":"Tuteja","year":"2016","journal-title":"Curr Genet Med Rep"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/cge.12881","article-title":"Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine","volume":"91","author":"Zaiou","year":"2017","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0066","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/pr.112.007252","article-title":"Pharmacogenetics and cardiovascular disease\u2013implications for personalized medicine","volume":"65","author":"Johnson","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0067","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/cts.12919","article-title":"Projected utility of pharmacogenomic testing among individuals hospitalized with COVID-19: a retrospective multicenter study in the United States","volume":"14","author":"Stevenson","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.jcf.2024.06.006_bib0068","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/pgs-2019-0185","article-title":"Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients","volume":"21","author":"Black","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.jcf.2024.06.006_bib0069","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2217\/pgs-2018-0049","article-title":"Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients","volume":"19","author":"Dong","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcf.2024.06.006_bib0070","series-title":"Medical genetics summaries","article-title":"Omeprazole Therapy and CYP2C19 Genotype","author":"Dean","year":"2012"},{"issue":"11","key":"10.1016\/j.jcf.2024.06.006_bib0071","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1124\/dmd.111.041293","article-title":"The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel","volume":"39","author":"Ogilvie","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.006_bib0072","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cts.13479","article-title":"Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis","volume":"16","author":"Anderson","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.006_bib0073","article-title":"Newborn screening for cystic fibrosis","author":"Southern","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.006_bib0074","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001402","article-title":"Newborn screening for cystic fibrosis","author":"Merelle","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.006_bib0075","article-title":"Newborn screening for cystic fibrosis","author":"Merelle","year":"2000","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:15:54Z","timestamp":1788246954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324007756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1569199324007756"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}